Sutro Biopharma, Inc.

Equities

STRO

US8693671021

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
4.15 ^USD	-4.60%		+8.36%	-3.26%

May. 08	BofA Securities Starts Sutro Biopharma With Buy Rating	MT
Apr. 30	Sutro Biopharma, Inc. Announces Initiation of Randomized Portion (Part 2) of REFRaME-O1 Trial	CI

Sutro Biopharma : 12th Annual World ADC London 2022 – Presentations

March 30, 2022 at 04:15 pm EDT

World ADC 2022 presentation titled, "Targeting FolRα in Gynecologic Cancers & other Solid Tumours with the Novel Antibody-Drug Conjugate, STRO-002" presented by Arturo Molina, MD, MS, Chief Medical Officer.

Attachments

Original Link
Original Document
Permalink

Disclaimer

Sutro Biopharma Inc. published this content on 30 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 March 2022 20:14:01 UTC.

Latest news about Sutro Biopharma, Inc.

BofA Securities Starts Sutro Biopharma With Buy Rating	May. 08	MT
Sutro Biopharma, Inc. Announces Initiation of Randomized Portion (Part 2) of REFRaME-O1 Trial	Apr. 30	CI
Piper Sandler Trims Price Target on Sutro Biopharma to $11 From $12, Maintains Overweight Rating	Apr. 03	MT
Truist Securities Adjusts Price Target on Sutro Biopharma to $18 From $25, Keeps Buy Rating	Apr. 03	MT
Ipsen and Sutro Biopharma Announce Exclusive Global Licensing Agreement for an ADC Targeting Solid Tumors	Apr. 02	CI
Ipsen: worldwide licensing agreement with Sutro Biopharma	Apr. 02	CF
Ipsen Signs Licensing Deal for Cancer-targeting Antibody Conjugate with Sutro Biopharma	Apr. 02	MT
Health Care Climbs on Weight-Loss Drug Excitement -- Health Care Roundup	Mar. 26	DJ
Wedbush Adjusts Sutro Biopharma's Price Target to $8 From $12, Maintains Outperform Rating	Mar. 26	MT
Sutro Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Transcript : Sutro Biopharma, Inc. - Special Call	Jan. 04
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRa-Targeting ADC	Jan. 04	CI
Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Sutro Biopharma, Inc. Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023	Dec. 11	CI
Vaxcyte Exercises Option for Manufacturing Rights Agreement With Sutro Biopharma; Sutro Shares Jump Premarket	Nov. 28	MT
Vaxcyte Exercises Option for Manufacturing Rights Agreement With Sutro Biopharma	Nov. 27	MT
Vaxcyte, Inc. Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control over Manufacturing and Development of Cell-Free Extract for Its Vaccine Candidates	Nov. 27	CI
Sutro Biopharma Promotes Jane Chung to Newly Created Position of COO	Nov. 21	MT
Sutro Biopharma, Inc Appoints Jane Chung as President and Chief Operating Officer	Nov. 21	CI
Piper Sandler Adjusts Price Target on Sutro Biopharma to $12 From $18, Maintains Overweight Rating	Nov. 15	MT
Earnings Flash (STRO) SUTRO BIOPHARMA Reports Q3 Revenue $16.9M	Nov. 13	MT
Sutro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Sutro Biopharma Says Endometrial Cancer Therapy Showed 'Encouraging Preliminary Anti-Tumor Activity'	23-10-23	MT
Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Endometrial Cancers At ESMO 2023	23-10-22	CI
Oppenheimer Initiates Coverage on Sutro Biopharma With Outperform Rating, $10 Price Target	23-10-06	MT

Chart Sutro Biopharma, Inc.

Duration

Period

More charts

Company Profile

Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Companyâs advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Sutro Biopharma, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.15 USD

Average target price

12.8 USD

Spread / Average Target

+208.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SUTRO BIOPHARMA, INC.	-3.26%	339M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs